MedTrace Logo

Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066

NCT00686504 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2010-12-10

No results posted yet for this study

Summary

The study is carried out in order to determine the relationship between AZD2066 exposure and mGluR5 receptor occupancy in the brain and to demonstrate that AZD2066 can displace \[11C\]AZ12713580 from mGluR5 binding-sites in the Central Nervous System

Conditions

  • Healthy

Interventions

DRUG

AZD2066

single dose of oral dose, 3 times per subject

DRUG

radioligand [11C] AZ12713580

single dose of iv administered 4 times per subject (3 times together with AZD2066)

Sponsors & Collaborators

Principal Investigators

  • Bo Fransson · Astrazeneca Clinical Pharmacology Unit, Stockholm, Sweden

  • Sophia Bengtsson · AstraZeneca R&D, Study Delivery, Clinical Development, Södertälje, Sweden

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00686504 on ClinicalTrials.gov